Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 288-292

  Katakami, Naoto ^a   Matsuhisa, Munehide ^a   Kaneto, Hideaki ^a   Matsuoka, Taka aki ^a   Sakamoto, Ken'ya ^a   Yasuda, Tetsuyuki ^a   Umayahara, Yutaka ^b   Kosugi, Keisuke ^b   Yamasaki, Yoshimitsu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Atherosclerosis; esRAGE; IMT; RAGE; sRAGE; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTERIAL CIRCULATION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE; MALE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CAROTID ARTERY, INTERNAL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; JAPAN; MULTIVARIATE ANALYSIS; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA; YOUNG ADULT;

EID: 61449087504     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.026     Document Type: Article

References (30)

1. Stern D.M., Yan S.D., Yan S.F., and Schmidt A.M. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1 (2002) 1-15
2. Schmidt A.M., Hasu M., Popov D., et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 91 (1994) 8807-8811
3. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
4. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95 (2004) 233-238
5. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267 (1992) 14998-15004
6. Sakurai S., Yonekura H., Yamamoto Y., et al. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 14 Suppl. 3 (2003) S259-S263
7. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 (2003) 1097-1109
8. Yonekura H., Yamamoto Y., Sakurai S., Watanabe T., and Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 97 (2005) 305-311
9. Hanford L.E., Enghild J.J., Valnickova Z., et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279 (2004) 50019-50024
10. Hudson B.I., Harja E., Moser B., and Schmidt A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol 25 (2005) 879-882
11. Sakurai S., Yamamoto Y., Tamei H., et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 73 (2006) 158-165
12. Shoji T., Koyama H., Morioka T., et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55 (2006) 2245-2255
13. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end-products. Nat Med 4 (1998) 1025-1031
14. Kislinger T., Tanji N., Wendt T., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21 (2001) 905-910
15. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
16. Sakaguchi T., Yan S.F., Yan S.D., et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111 (2003) 959-972
17. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 (2005) 2716-2721
18. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2587-2593
19. Katakami N., Kaneto H., Matsuhisa M., and Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 190 (2007) 22-23
20. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
21. Humpert P.M., Djuric Z., Kopf S., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6 (2007) 9
22. Dupont W.P., and Plummer W.D. Power and sample size calculations: a review and computer program. Control Clin Trials 11 (1990) 116-128
23. Yamasaki Y., Kawamori R., Matsushima H., et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 43 (1994) 634-639
24. Kawamori R., Yamasaki Y., Matsushima H., et al. Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 15 (1992) 1290-1294
25. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
26. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the Epidemiology of Diabetes Interventions and Complications. Diabetes 48 (1999) 383-390
27. Ludwig M., Kraft K., Rucker W., and Huther A.M. Diagnosis of very early arteriosclerotic vascular wall changes using duplex sonography. Klin Wochenscler 67 (1989) 442-446
28. Handa N., Matsumoto M., Maeda H., et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 21 (1990) 1567-1572
29. Koyama H., Shoji T., Fukumoto S., et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27 (2007) 147-153
30. Geroldi D., Falcone C., Minoretti P., et al. High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54 (2004) 1149-1150